title: Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation.
abstract: Prognostic factors in 42 patients aged 11 to 62 (median 46) years, with myelodysplastic syndrome (MDS) or after leukemic transformation, who underwent allogeneic marrow transplantation between 1984 and 1999 were analyzed. Thirty-six had advanced disease morphology; 19 had leukemic transformation. Twenty-nine received a preparative regimen of BuCy2 and 13 busulfan 14 mg/kg, etoposide 50 mg/kg and cyclophosphamide 120 mg/kg. Severe hepatic veno-occlusive disease (VOD) occurred in three patients all of whom received anti-leukemic chemotherapy prior to transplantation. Fifteen patients (36%) died from early transplant-related complications; nine patients relapsed. The estimated 4 year disease-free survival (DFS) was 35% (95% CI 26-44%). Older age was the most significant adverse prognostic factor. Patients with leukemic transformation who underwent early transplantation had significantly better DFS than those treated first with chemotherapy (P = 0.002). Delayed toxicity was rare in these patients; no late relapses occurred. Bone Marrow Transplantation (2000) 25, 1219-1222.
authors.affiliation: Bone Marrow Transplantation Program, Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University Medical Center, Columbus, Ohio 43210, USA.
authors.forename: E A
authors.initials: EA
authors.lastname: Copelan
authors.forename: S L
authors.initials: SL
authors.lastname: Penza
authors.forename: P J
authors.initials: PJ
authors.lastname: Elder
authors.forename: S A
authors.initials: SA
authors.lastname: Ezzone
authors.forename: M D
authors.initials: MD
authors.lastname: Scholl
authors.forename: T P
authors.initials: TP
authors.lastname: Bechtel
authors.forename: P S
authors.initials: PS
authors.lastname: Belt
authors.forename: B R
authors.initials: BR
authors.lastname: Avalos
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage*; D002648:Child; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007938:Leukemia / Q000503:physiopathology / Q000628:therapy*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000503:physiopathology / Q000628:therapy*; D011379:Prognosis; D014184:Transplantation, Homologous
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D002066:Busulfan